Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU
- The EC has approved Byooviz (biosimilar- ranibizumab) in the EU for the treatment of Ophthalmic disease
- Lucentis is used to treat ophthalmic disease & macular degeneration. Byooviz marks the 1st biosimilar referencing Lucentis to be commercialized in the EU
- Samsung Bioepis & Biogen also plans to commercialize an aflibercept biosimilar SB15 which is currently in a P-III trial. Additionally- Samsung Bioepis has a pipeline of 10 products and blockbuster biosimilar products in its portfolio
Ref: Business wire | Image: Samsung Bioepis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].